Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds

@inproceedings{Carrella2016ComputationalDR,
  title={Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds},
  author={Diego Carrella and Isabella Manni and Barbara Tumaini and Rosanna Dattilo and Federica Papaccio and Margherita Mutarelli and Francesco Sirci and Carla Azzurra Amoreo and Marcella Mottolese and Manuela Iezzi and Laura Ciolli and Valentina Aria and Roberta Bosotti and Antonella Isacchi and Fabrizio Loreni and Alberto Bardelli and Vittorio Enrico Avvedimento and Diego di Bernardo and Luca Cardone},
  booktitle={Oncotarget},
  year={2016}
}
The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunities in cancer and other human diseases. Given that gene expression signatures can be associated with specific oncogenic mutations, we tested whether a "reverse" oncogene-specific signature might… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

Similar Papers

Loading similar papers…